Gastroenteropancreatic Neuroendocrine Tumor Patients Imaged Favorably with Somatostatin Receptor Antagonist: Results of a Phase I/II Study Comparing $^{68}$Ga-OPS202 with $^{68}$Ga-DOTATOC PET/CT

Guillaume P. Nicolas$^1$; Felix Kaul$^1$; Ramon Mena$^2$; Hakim Bouterfa$^2$; Michael Lassmann$^3$; Nils Schreiter$^4$; Melpomeni Fani$^1$; Damian Wild$^1$

$^1$Division of Nuclear Medicine, University of Basel Hospital, Basel, Switzerland
$^2$OctreoPharm Sciences GmbH, Berlin, Germany
$^3$Department of Nuclear Medicine, University Hospital Wuerzburg, Germany
$^4$Department of Radiology, Charité, Universitätsmedizin Berlin, Germany

**Background:** Radiolabeled somatostatin (sst) receptor antagonists are a promising class of radiotracer for imaging and treatment of neuroendocrine tumor patients. We report here the first clinical data on $^{68}$Ga-OPS202 PET/CT in gastroenteropancreatic neuroendocrine tumors (GEP-NET) (ClinicalTrials.gov NCT02162446).

**Methods:** Metastatic G1/G2 GEP-NET patients, with at least 1 tumor focus on previous $^{68}$Ga-DOTATOC PET/CT, were screened for eligibility in an open-label, micro-dosing study. Safety, biodistribution, dosimetry of two single doses of $^{68}$Ga-OPS202 (A: 15μg & B: 50μg) and preliminary efficacy in comparison with $^{68}$Ga-DOTATOC PET/CT were investigated. $^{68}$Ga-OPS202 doses were given within 3-4 weeks interval. All PET/CT were performed on the same scanner, >4 weeks after sst-analogs had been stopped and 1h after i.v. injection of the radiotracer.
Results: Twelve patients were recruited (7 male, 5 female). No grade 3 or serious adverse event (AE) related to $^{68}$Ga-OPS202 occurred. Both $^{68}$Ga-OPS202 doses (A & B) showed significantly lower uptake in the liver (mean SUVmax±σ) 3.2±0.8 (A)/2.9±0.7 (B), in the spleen 11.7±4.2 (A)/10.1±2.3 (B), in the intestine 3.5±1.3 (A)/2.9±0.7 (B) and in the pancreas 3.2±2.0 (A)/2.6±1.4 than $^{68}$Ga-DOTATOC, respectively 6.8±2.3, 29.1±10.0, 5.4±1.0 and 4.9±3.2 (p<0.05). Matched lesions (lesions visible on all 3 scans) did not differ significantly in terms of tumor uptake (median SUVmax [range]) 10.2[1.4 – 155.5] (A)/9.6 [1.3 – 130.2] (B) vs 10.7[1.2-141.7] for $^{68}$Ga-DOTATOC. Liver-metastases-to-liver-background uptake ratios consistently improved >2-fold (mean±σ) 5.7±6.9 (A)/6.0±7.4 (B) vs 3.0±1.9 for $^{68}$Ga-DOTATOC resulting in a higher detection rate of liver metastases for $^{68}$Ga-OPS202 PET/CT (median) 13 (A), 15 (B) vs 4 liver metastases for $^{68}$Ga-DOTATOC. The effective dose for an injection of 150 MBq Ga-68-OPS202 is 3.6 mSv (mean±σ: 2.4 ±1.78E-02 mSv/MBq).

Conclusion: $^{68}$Ga-OPS202 is well tolerated and shows increased image contrast compared to $^{68}$Ga-DOTATOC PET/CT. The lower hepatic and intestinal and pancreatic uptake may increase the sensitivity and diagnostic confidence in staging GEP-NETs.
Tumor-to-Background Uptake Ratios
Patient 10

Median SUVmax of all matched lesions
n = 89 lesions in 12 pts

88Ga-DOTATOC

Ga-68-DOTATOC
Ga-68-OPS202-15μg (A)

68Ga-OPS202 15 μg

G. P. Nicolas